Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers
about
Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cellsA Chemical Probe for the ATAD2 BromodomainAcetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and CancerBET domain co-regulators in obesity, inflammation and cancerGenome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesisMultiple cancer testis antigens function to support tumor cell mitotic fidelity.miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis.Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target.Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372.Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammationIntegrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.Fragment-based screening of the bromodomain of ATAD2.Lessons from yeast on emerging roles of the ATAD2 protein family in gene regulation and genome organization.Maintenance of nucleosomal balance in cis by conserved AAA-ATPase Yta7.ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative ResectionQuantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.Abo1, a conserved bromodomain AAA-ATPase, maintains global nucleosome occupancy and organisation.Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signalingIntegrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene ExpressionGene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis.Chemical synthesis of the ATAD2 bromodomain.Significance of PRO2000/ANCCA expression, a novel proliferation-associated protein in hepatocellular carcinoma.The bromodomain interaction module.Combined proteomic and in silico approaches to decipher post-meiotic male genome reprogramming in mice.Regulation of histone gene transcription in yeast.Bromodomains and their pharmacological inhibitors.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Progress in the Development of non-BET Bromodomain Chemical Probes.Epigenomic regulation of oncogenesis by chromatin remodeling.Biological function and histone recognition of family IV bromodomain-containing proteins.Structural features and inhibitors of bromodomains.Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication.Restriction of histone gene transcription to S phase by phosphorylation of a chromatin boundary protein.ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells.
P2860
Q27696569-888FF082-3B1A-4814-9586-ED0F8703070EQ27702290-9A92A54B-221A-4EC9-90D1-6BFBA760316FQ27727700-965303CA-F7CF-44EE-A2CC-27E5A9C75868Q28076086-154A99FE-82C8-4CBD-BAF8-A29CC80C73FAQ28269301-114B9E60-2AD5-4AB2-93E8-CA70B9BD4B68Q28488081-2EF94631-26E8-4ABC-B235-D28099CAD233Q29871492-F33FAD89-36F1-4D98-8472-9A4899EA1C38Q33592473-740570D9-9598-4854-9887-66B46BDE4155Q33670486-C34C7AE9-320E-4964-8BCE-A4C3A393F8D2Q33738076-7113EE1E-5DB4-422A-AFCE-E8930D0D0523Q33798405-41414E3C-5674-40DA-BB5F-F13F6E25F8ABQ34069945-227120D6-35CF-4556-B8B1-BCAB60ED7B25Q34513460-6D27E3B4-A23D-422F-B2AB-FCD9D8903A98Q34580883-482B5E7B-557F-4DA3-B951-FF7AAD8B23E0Q34631628-8DAF8147-8A70-476C-BA72-5ACA7233E8E0Q34768072-AB09F4E5-CCFB-4AE7-B38D-B66FF9911311Q34864047-B7B60A29-93D5-4ED3-AC2A-BA5FDCD87F97Q36186943-F55044C1-73DC-4E30-B6E4-1126387D02C5Q36386895-BD138220-24AF-42E2-A880-59AD45AF6E5EQ36414073-9B85AB4B-C525-48D0-A63D-6C5C895746F4Q36478645-0FB1732B-6C25-4DCB-A9CE-4B788AE0A684Q36561575-A89E4419-0527-4266-803E-33B3305A348DQ36790044-3D39260E-BA17-477A-BB46-A14527E81C40Q37407194-A43167EC-DDAD-4541-B03B-472A10E8047DQ37612735-3AC73156-93CF-43CE-A2E1-62DDDFF866B5Q37719344-F37F0137-F680-4F5C-9A98-6EC17DCF2AC1Q38019699-B107A124-76B4-4A48-8BF1-FA98D42A1C08Q38025676-FA04A968-6AE4-4EBC-AC4F-D3E66F2A3879Q38131283-D4CFD42B-6E2D-434F-9FA0-0E54EEE8616BQ38185355-7EE579D7-3B32-49D7-A2FF-20C39729F7ABQ38233723-F38ADC67-1489-4573-B1B4-019CA21E4995Q38691377-B8BFACF6-C2C6-4F5F-9070-8A31E1BD7631Q38709544-96CF6370-5C89-461E-8427-DA5D2785A574Q38788315-6CA52418-9A9D-47BA-AC5C-DFEE9E23919AQ38987705-DA929836-B085-454A-9E38-788A88DE0AA0Q39265572-D7A0A8DF-C861-4D06-A54D-4BD5C60606AAQ39340075-C00B0CF3-0F95-4189-8BB3-754348B2CE3EQ39406153-FA6A9671-9D31-478C-B3BF-DBDAB50F8AE4Q39923722-91BAE7DC-93A2-4A71-AFE0-DAD0397729B0Q40178846-79971F7A-0269-42FB-84A5-E286F5DBD514
P2860
Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers
description
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2010
@ast
im September 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2010/09/16)
@sk
vědecký článek publikovaný v roce 2010
@cs
wetenschappelijk artikel (gepubliceerd op 2010/09/16)
@nl
наукова стаття, опублікована у вересні 2010
@uk
مقالة علمية (نشرت في 16-9-2010)
@ar
name
Functional characterization of ...... sis in breast and lung cancers
@ast
Functional characterization of ...... sis in breast and lung cancers
@en
Functional characterization of ...... sis in breast and lung cancers
@nl
type
label
Functional characterization of ...... sis in breast and lung cancers
@ast
Functional characterization of ...... sis in breast and lung cancers
@en
Functional characterization of ...... sis in breast and lung cancers
@nl
prefLabel
Functional characterization of ...... sis in breast and lung cancers
@ast
Functional characterization of ...... sis in breast and lung cancers
@en
Functional characterization of ...... sis in breast and lung cancers
@nl
P2093
P3181
P356
P1433
P1476
Functional characterization of ...... sis in breast and lung cancers
@en
P2093
A. Debernardi
C. Brambilla
C. Lestrat
E. Brambilla
E. Escoffier
S. Rousseaux
V. Virolle
P2888
P304
P3181
P356
10.1038/ONC.2010.259
P407
P577
2010-09-16T00:00:00Z
P5875
P6179
1004072341